

Shaping Tomorrow's Biopharma 4.0 Technologies, Tools and Collaboration

The current paradigm shift and digital transformation in biomanufacturing will result in a facility of the future that is truly an ecosystem of intensified, connected & continuous processing seamlessly coupled with uninterrupted data acquisition and analysis. Together, this will make real-time lot release and lights-out manufacturing achievable to the ultimate benefit of patients around the globe, expanding access to affordable life-saving and life-enhancing biotherapeutics.

Short presentations will set the scene for a **panel discussion – sharing and discussing real-world insights and perspectives.**

Which inline PAT/QbD tool can contribute to achieving your bioprocessing 4.0 strategy?

Raman combined with chemometric modeling is a standard solution for inline, real-time monitoring of CPPs/CQAs. Improved production capacity and desired product quality can be achieved by controlling the monitored CPPs/CQAs within a specified design space.

Speaker: Fabien Caron
Product Manager, Process Monitoring Solutions, Merck

How can advanced high throughput techniques, analytical methods, and statistical tools be applied to develop optimal perfusion cell culture media?

Next-gen media optimization requires collecting and interpreting large amounts of data through testing large numbers of formulations, analyzing the samples for critical attributes, and using advanced statistical tools to interpret the results. In this talk we describe how we connect all these tools to improve perfusion media development capabilities.

Speaker: Jeremiah Riesberg, PhD
R&D Senior Scientist, Cell Sciences and Development, Bioprocessing, Merck

What's the Best Approach to Optimize Process Yield with N-1 Perfusion Technology at Early and Late Phase?

We will share real-world data from three approaches to N-1 perfusion fitted to the process, development phase, and ultimately to the program's goals.

Speaker: Céline Raymond, PhD
Upstream Process Development Manager, Biologics & Viral Vectors CDMO, Merck

A new hero: Novel technologies for virus detection in biologics testing

While uncommon, contamination events have devastating consequences on biological production in terms of patient supply and clean-up costs. Come and learn about novel methods that are at the forefront of detection of viral contamination and how these are likely to impact biosafety testing as the industry moves to continuous production.

Speaker: Alison Armstrong, PhD
Global Head of Technical & Scientific Solutions, Contract Testing Services, Merck